


Generalized Myasthenia Gravis Market and Epidemiology Forecast 2032: Population Data, Drugs, Companies | DelveInsight

DelveInsight's Generalized Myasthenia Gravis Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM.

LAS VEGAS, NEVADA, UNITED STATES, March 26, 2024 /EINPresswire.com/ -- DelveInsight's "Generalized Myasthenia Gravis Market Insights, Epidemiology, and Market Forecast-2032" report offers an in-depth understanding of the Generalized Myasthenia Gravis, historical and forecasted epidemiology as well as the Generalized Myasthenia Gravis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.



To Know in detail about the Generalized Myasthenia Gravis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; [Generalized Myasthenia Gravis Market Forecast](#).

Some of the key facts of the Generalized Myasthenia Gravis Market Report:

The Generalized Myasthenia Gravis market size was valued approximately USD 2,700 million in 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032).

In 2021, the market size for Generalized Myasthenia Gravis (gMG) across the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan was estimated to be around USD 2,700 million.

According to Suresh et al. (2021), there are 20 cases of myasthenia gravis for every 100,000 people in the United States. It shows that those under 40 have a higher female predominance, while people over 50 have a higher male predominance.

The prevalence of MG varies from 1.5 to 17.9, or 2.19 to 36.71 cases/100.000 population, depending on the region. This suggests that there are roughly 60.000 sufferers in the US and

56,000–123,000 in Europe.

According to a Green et al. (2020) study, 5.6% of the North American sample had non-family myasthenia gravis. While the majority of instances of myasthenia gravis are still not familial, a prevalence of 5.6% is several hundred times higher than the overall prevalence of 1 in 5–10 000 cases of the condition.

Key Generalized Myasthenia Gravis Companies: Viela Bio, UCB Pharma, Ra Pharmaceuticals, Argenx, Alexion Pharmaceuticals, Takeda, Argenx-Halozyme Therapeutics, Horizon Therapeutics, Hoffmann-La Roche, Janssen Research & Development, LLC, Immunovant Sciences GmbH, Sanofi, Cartesian Therapeutics, Takeda, DAS Therapeutics, Inc., and others

Key Generalized Myasthenia Gravis Therapies: Inebilizumab, Rozanolixizumab, Zilucoplan, Efgartigimod, Eculizumab, TAK-079, Subcutaneous Efgartigimod, Uplizna (Inebilizumab), Enspryng (Satralizumab), Nipocalimab, Batoclimab, Tolebrutinib, Descartes-08, Mezagitamab (TAK-079), DAS-001, and others.

The Generalized Myasthenia Gravis epidemiology based on gender analyzed that prevalence of Generalized Myasthenia Gravis is higher in females than males.

The Generalized Myasthenia Gravis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Generalized Myasthenia Gravis pipeline products will significantly revolutionize the Generalized Myasthenia Gravis market dynamics.

Generalized Myasthenia Gravis Overview

Generalized Myasthenia Gravis (gMG) is a chronic autoimmune neuromuscular disorder characterized by muscle weakness and fatigue, particularly during periods of activity. It occurs when the immune system mistakenly attacks the neuromuscular junctions, which are the areas where nerve cells connect with muscles, leading to impaired communication between nerves and muscles.

Get a Free sample for the Generalized Myasthenia Gravis Market Report:

https://www.delveinsight.com/report-store/generalized-myasthenia-gravis-gmg-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=gpr

Generalized Myasthenia Gravis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Generalized Myasthenia Gravis Epidemiology Segmentation:

The Generalized Myasthenia Gravis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Generalized Myasthenia Gravis

Prevalent Cases of Generalized Myasthenia Gravis by severity

Gender-specific Prevalence of Generalized Myasthenia Gravis

Diagnosed Cases of Episodic and Chronic Generalized Myasthenia Gravis

Download the report to understand which factors are driving Generalized Myasthenia Gravis epidemiology trends @ [Generalized Myasthenia Gravis Epidemiology Forecast](#)

Generalized Myasthenia Gravis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Generalized Myasthenia Gravis market or expected to get launched during the study period. The analysis covers Generalized Myasthenia Gravis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Generalized Myasthenia Gravis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Generalized Myasthenia Gravis Therapies and Key Companies

Inebilizumab: Viela Bio

Rozanolixizumab: UCB Pharma

Zilucoplan: Ra Pharmaceuticals

Efgartigimod: Argenx

Eculizumab: Alexion Pharmaceuticals

TAK-079: Takeda

Subcutaneous Efgartigimod: Argenx-Halozyme Therapeutics

Uplizna (Inebilizumab): Horizon Therapeutics

Enspryng (Satralizumab): Hoffmann-La Roche

Nipocalimab: Janssen Research & Development, LLC

Batoclimab: Immunovant Sciences GmbH

Tolebrutinib: Sanofi

Descartes-08: Cartesian Therapeutics

Mezagitamab (TAK-079): Takeda

DAS-001: DAS Therapeutics, Inc.

Scope of the Generalized Myasthenia Gravis Market Report

Study Period: 2019–2032

Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

Key Generalized Myasthenia Gravis Companies: Viela Bio, UCB Pharma, Ra Pharmaceuticals, Argenx, Alexion Pharmaceuticals, Takeda, Argenx-Halozyme Therapeutics, Horizon Therapeutics, Hoffmann-La Roche, Janssen Research & Development, LLC, Immunovant Sciences GmbH, Sanofi, Cartesian Therapeutics, Takeda, DAS Therapeutics, Inc., and others

Key Generalized Myasthenia Gravis Therapies: Inebilizumab, Rozanolixizumab, Zilucoplan, Efgartigimod, Eculizumab, TAK-079, Subcutaneous Efgartigimod, Uplizna (Inebilizumab), Enspryng (Satralizumab), Nipocalimab, Batoclimab, Tolebrutinib, Descartes-08, Mezagitamab (TAK-079), DAS-001, and others

Generalized Myasthenia Gravis Therapeutic Assessment: Generalized Myasthenia Gravis current marketed and Generalized Myasthenia Gravis emerging therapies

Generalized Myasthenia Gravis Market Dynamics: Generalized Myasthenia Gravis market drivers and Generalized Myasthenia Gravis market barriers

Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

Generalized Myasthenia Gravis Unmet Needs, KOL's views, Analyst's views, Generalized Myasthenia Gravis Market Access and Reimbursement

To know more about Generalized Myasthenia Gravis companies working in the treatment market, visit @ [Generalized Myasthenia Gravis Clinical Trials and Therapeutic Assessment](#)

Table of Contents

1. Generalized Myasthenia Gravis Market Report Introduction
2. Executive Summary for Generalized Myasthenia Gravis
3. SWOT analysis of Generalized Myasthenia Gravis
4. Generalized Myasthenia Gravis Patient Share (%) Overview at a Glance
5. Generalized Myasthenia Gravis Market Overview at a Glance
6. Generalized Myasthenia Gravis Disease Background and Overview
7. Generalized Myasthenia Gravis Epidemiology and Patient Population
8. Country-Specific Patient Population of Generalized Myasthenia Gravis
9. Generalized Myasthenia Gravis Current Treatment and Medical Practices
10. Generalized Myasthenia Gravis Unmet Needs
11. Generalized Myasthenia Gravis Emerging Therapies
12. Generalized Myasthenia Gravis Market Outlook
13. Country-Wise Generalized Myasthenia Gravis Market Analysis (2019–2032)
14. Generalized Myasthenia Gravis Market Access and Reimbursement of Therapies
15. Generalized Myasthenia Gravis Market Drivers
16. Generalized Myasthenia Gravis Market Barriers
17. Generalized Myasthenia Gravis Appendix
18. Generalized Myasthenia Gravis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Gaurav Bora

DelveInsight Business Research

+1 469-945-7679

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/698910187>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.